# A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

> **NCT02681094** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 905 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Inadequate Glycaemic Control

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo for Dapagliflozin
- **DRUG:** Saxagliptin
- **DRUG:** Placebo for Saxagliptin

## Key facts

- **NCT ID:** NCT02681094
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-26
- **Primary completion:** 2017-07-15
- **Final completion:** 2017-07-15
- **Target enrollment:** 905 (ACTUAL)
- **Last updated:** 2018-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02681094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02681094, "A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT02681094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*